Advancing SolexanTM, a proprietary topical antiviral platform treatment for shingles infections.
Phase Ib trial completed demonstrating safety and tolerability.
Patent and trademark protection across key markets.
ZosterEaseTM trial to address the global shingles market.
Based in Melbourne, Australia and Missoula, USA.
Wintermute Biomedical has signed a MoU with Ego Pharmaceuticals to support further clinical development of Solexan™ and explore future commercialisation opportunities in Australia and selected international markets.
Wintermute Biomedical strengthens its board credentials with the announcement of Prof. Skerritt, former head of Australia's Therapeutic Goods Administration.
World's first validated, lab-based model of oral gonorrhoea infection using human oral cells
Simply fill out the form to download our Investor Deck materials or reach out to our team.
Information is for investors and potential partners; not for promotional use.
Thank you, your form has been received.
